US Bancorp DE Purchases 1,610 Shares of Fresenius Medical Care AG (NYSE:FMS)

US Bancorp DE increased its stake in Fresenius Medical Care AG (NYSE:FMS) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,429 shares of the company’s stock after buying an additional 1,610 shares during the quarter. US Bancorp DE’s holdings in Fresenius Medical Care were worth $463,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. QRG Capital Management Inc. increased its stake in shares of Fresenius Medical Care by 16.7% during the fourth quarter. QRG Capital Management Inc. now owns 67,973 shares of the company’s stock valued at $1,539,000 after buying an additional 9,706 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Fresenius Medical Care by 5.8% during the fourth quarter. Bank of New York Mellon Corp now owns 21,951 shares of the company’s stock worth $497,000 after purchasing an additional 1,205 shares during the period. Arbor Investment Advisors LLC acquired a new stake in shares of Fresenius Medical Care during the fourth quarter worth about $200,000. Callan Capital LLC acquired a new position in Fresenius Medical Care in the fourth quarter valued at approximately $297,000. Finally, Venturi Wealth Management LLC lifted its holdings in Fresenius Medical Care by 8.4% in the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock valued at $129,000 after acquiring an additional 441 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $24.18 on Thursday. The stock’s 50-day moving average is $23.61 and its two-hundred day moving average is $22.13. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.25. The company has a market cap of $14.19 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99.

Analyst Ratings Changes

A number of research firms have recently commented on FMS. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial boosted their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Finally, StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.